Platform combining phenotypic high content imaging analysis and three-dimensional models of fresh patient tumors to provide relevant analysis of drug responses that can inform candidate selection and clinical program design
Crown Bioscience Launches ‘3D Ex Vivo Patient Tissue Platform’ to Improve Response Predictability to Immuno-Oncology Drug Candidates
Topics: RR & IVD
MBL to Distribute Qkine’s Animal-free Growth Factors and Cytokines
Tokyo, Japan - September 30, 2021 - Medical & Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences Company, has signed a distributor agreement with Qkine Ltd. for sale of products in Japan.
Topics: RR & IVD
MBL establishes a new R&D and manufacturing site for in vitro diagnostic products and services in Shenzhen, China
Shenzhen, China - September 17, 2021 - Medical and Biological Laboratories Co., Ltd. (President & CEO: Kimimasa Yamada, “MBL”), a JSR Life Sciences Company, announced that its subsidiary MBL Shenzhen Biotech Co., Ltd. (“MBLS”) has been established in full-scale operation as a new R&D and manufacturing site for in vitro diagnostic products and services in China.
Topics: Corporate RR & IVD
MBL Launches New Automated Analyzer Kit to Quickly Detect Neutralizing Antibodies Against SARS-CoV-2
Kit will help with understanding immune status of COVID-19 patients and promote research on vaccine efficacy
Topics: RR & IVD
MBL International Launches QuickSwitch™ Class II Custom MHC Tetramer Kits
Woburn, MA – July 28, 2021 – MBL International, a JSR Life Sciences company, recently announced commercial availability of QuickSwitch™ Class II Custom MHC Tetramer Kits. QuickSwitch kits for Class II MHC Tetramers for analysis of CD4+ T cells have been created to meet the needs of scientists looking for better understanding of the CD4+ T cell responses.
Topics: RR & IVD
New NAFLD/NASH Preclinical Model Data to be Presented at ADA 2020
San Diego, Calif – June 9, 2020 — Crown Bioscience today announced the presentation of new, proprietary NAFLD/NASH preclinical model development data. The data will be available at the American Diabetes Association (ADA) 80th Scientific Sessions, as well as CrownBio’s own complementary virtual event.